Provention Bio, Inc. (PRVB) News
Filter PRVB News Items
PRVB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRVB News Highlights
- PRVB's 30 day story count now stands at 7.
- Over the past 29 days, the trend for PRVB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PRVB are BIO, HTGC and LOAN.
Latest PRVB News From Around the Web
Below are the latest news stories about PROVENTION BIO INC that investors may wish to consider to help them evaluate PRVB as an investment opportunity.
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences. |
Should You Invest in Provention Bio (PRVB)?Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder Class returned 3.4% compared to a 7.6% return for the S&P 500 Index. Since its inception in April 2022, the fund returned 5.0% compared to a -14.2% […] |
Market Sentiment Around Loss-Making Provention Bio, Inc. (NASDAQ:PRVB)Provention Bio, Inc. ( NASDAQ:PRVB ) is possibly approaching a major achievement in its business, so we would like to... |
Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains?In last trading session, Provention Bio Inc. (NASDAQ:PRVB) saw 1.15 million shares changing hands with its beta currently measuring 2.30. Company’s recent per share price level of $9.10 trading at $0.22 or 2.48% at ring of the bell on the day assigns it a market valuation of $780.69M. That closing price of PRVB’s stock is … Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains? Read More » |
Provention Bio Announces the Grant of Inducement AwardsProvention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) a |
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of DirectorsProvention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors. Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, Inc., AbbVie, Abbott Laboratories, and G.D. Searle and Co. prior to the latter's merger with Pharmacia & Upjohn |
Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This YearProvention Bio Inc. (NASDAQ:PRVB) has a beta value of 2.30 and has seen 1.53 million shares traded in the last trading session. The company, currently valued at $829.59M, closed the last trade at $9.67 per share which meant it lost -$0.9 on the day or -8.51% during that session. The PRVB stock price is -9.82% … Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This Year Read More » |
Provention Bio: Tzield Approved, But Neutral On Commercial LaunchProvention Bio''s Tzield approved by the FDA. Read more to see why we''re optimistic about PRVB stock but are on the sidelines for now. |
12 Best 52-Week High Stocks To Buy NowIn this article, we will take a look at the 12 best 52-week high stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best 52-Week High Stocks To Buy Now. The equity markets have been taking a beating this year as the Dow Jones Industrial Average […] |
12 Best Biotech Stocks to Buy Under $10In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10. The past two years have been challenging for the biotech sector, based on the market performance of biotech equities. Compared to […] |